Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

Summary

Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas

Eligibility

Inclusion Criteria:

1. Age 14-80 years.
2. Histologically confirmed advanced SPTP with ER/PR+.
3. Advanced disease:

   * Unresectable primary tumor or distant metastasis (liver, lung, peritoneum, etc.).
   * Recurrent or refractory after prior surgery/systemic therapy.
4. ≥1 measurable lesion.
5. ECOG performance status 0-2.
6. Life expectancy ≥1 month.
7. Able to comply with study visits and oral medication.

Exclusion Criteria:

1. Non-SPTP pathology.
2. Active gastrointestinal inflammation/infection (e.g., pancreatitis).
3. Pregnancy/lactation.
4. Severe organ dysfunction (renal, cardiac, hepatic, or pulmonary).
5. Uncontrolled comorbidities (e.g., CNS disorders, unstable angina).
6. Conditions compromising patient safety or data integrity.

Conditions2

Interventions1

Related trials

• Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer — SOLTI Breast Cancer Research Group
• Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ — Institut Cancerologie de l'Ouest

Browse More Trials